First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors - ScienceDirect

Emerging roles of fatty acid metabolism in cancer and their

FASN inhibitor TVB-3166 prevents S-acylation of the spike protein

Acetyl-CoA metabolism as a therapeutic target for cancer

First-in-human study of the safety, pharmacokinetics, and

Frontiers Translational Pharmacokinetic–Pharmacodynamic Modeling

TVB-2640 (Denifanstat, Fatty Acid Synthase Inhibitor 2, FASN-IN-2

Emerging roles of fatty acid metabolism in cancer and their

Lipids and cancer: Emerging roles in pathogenesis, diagnosis and

ncRNA-mediated fatty acid metabolism reprogramming in HCC

Frontiers First-In-Human Study to Assess the Safety

Novel, first-in-class, fatty acid synthase inhibitor, TVB-2640